Abstract
Overview
Introduction
The high prevalence of nicotine dependence, strong uptake of Pfizer' s Chantix
(varenicline), and the launch of new innovative therapies will cause the
nicotine dependence prescription drug market to grow to $4.6 billion across
the seven major markets by 2016. Innovative therapies are set to offer
patients a convenient dosing regimen and thereby carrying the potential for
improved compliance.
Scope
- Analysis of patient potential, unmet needs and clinical trial design in
nicotine dependence
- Overview of the current nicotine dependence market, covering both
prescription and OTC products
- Overview of drugs in late stage clinical development for nicotine
dependence
- Profiles of key compounds in development for use in nicotine dependence,
with forecasts of drug revenues to 2016 and insight from key opinion leaders
Highlights
Nicotine vaccines are the most prevalent drug class in the late-stage
pipeline. This represents a move away from nicotine replacement and nicotine
agonist therapies, which have historically dominated the market. Datamonitor
predicts nicotine vaccine companies will be important players in the market by
2016, led by Novartis' s NIC-002.
Nicotine vaccines are designed to prevent nicotine from entering the brain and
thus reduce the pleasurable effect of smoking. The utility of vaccines in
nicotine dependence lies in the long-term protection they provide along with
minimal patient compliance and carry the potential for prophylactic use.
With two compounds in late-stage development for the treatment of nicotine
dependence, it is evident that Sanofi-Aventis is keen to penetrate this
market. Although possessing a similar mechanism of action to Chantix,
Datamonitor believes that the drug' s shorter treatment course than the market
leader represents a strong competitive advantage.
Reasons to Purchase
- Understand unmet needs and opportunities in this market based on the
comments of interviewed key opinion leaders.
- Benchmark key late-stage nicotine dependence compounds against the current
market leader.
- Assess the seven major market total sales forecasts of key late-stage
pipeline drugs; and examine their clinical and commercial potential
| 
View Cart
